Mind to Market

Tuesday, August 21, 2007

AutoGenomics' Warfarin Panel

GenomicWeb News (sub required) reported on Harvard-Partners Center for Genetics and Genomics' completion of an evaluation of AutoGenomics' Infiniti 2C9-VKORC1 assay; a genetic test to determine correct dosing for warfarin. This announcement has come on the heels of the FDA's approval of new labeling for warfarin suggesting that an individual's response to the drug is dependent upon their genetic makeup.

HPCGG is participating in a clinical trial entitled: Creating an Optimal Warfarin Nomogram Trial (CROWN) to incorporate both clinical and genetic information in determining the correct warfarin dosing.

Labels: , , , ,


Post a Comment

Subscribe to Post Comments [Atom]


Create a Link

<< Home